Does Rallies track congressional trades in GILD?

Yes. Rallies tracks politician and congressional stock disclosures for GILD, including reported purchases, sales, dates, owners, and trade amounts when available.

Is GILD research on Rallies investment advice?

No. Rallies provides research, data, and educational context for GILD. It does not provide personalized investment advice.

GILD (Gilead Sciences) Stock Analysis - Politician Trades

Gilead Sciences (GILD) is a publicly traded Healthcare sector company. As of May 20, 2026, GILD trades at $130.15 with a market cap of $160.99B and a P/E ratio of 17.61. GILD moved +0.10% today. Year to date, GILD is +10.47%; over the trailing twelve months it is +19.78%. Its 52-week range spans $82.82 to $157.29. Analyst consensus is strong buy with an average price target of $159.83. Rallies surfaces GILD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Which politicians traded GILD stock?

Recent politician trading activity in GILD includes disclosures from Josh Gottheimer, Val Hoyle, Marjorie Taylor Greene, Josh Gottheimer, and Marjorie Taylor Greene. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.

GILD Key Metrics

Key financial metrics for GILD
Metric	Value
Price	$130.15
Market Cap	$160.99B
P/E Ratio	17.61
EPS	$7.42
Dividend Yield	0.82%
52-Week High	$157.29
52-Week Low	$82.82
Volume	3.70M
Avg Volume	0
Revenue (TTM)	$29.74B
Net Income	$9.22B
Gross Margin	79.36%

Congressional Trades in GILD

Josh Gottheimer purchase GILD on Jan 27, 2026 (amount: $15.00K) for Joint.
Val Hoyle sale GILD on Sep 23, 2025 (amount: $15.00K) for Spouse.
Marjorie Taylor Greene purchase GILD on Jun 6, 2025 (amount: $15.00K).
Josh Gottheimer sale GILD on May 14, 2025 (amount: $15.00K) for Joint.
Marjorie Taylor Greene purchase GILD on May 5, 2025 (amount: $15.00K).

Latest GILD News

Gilead Sciences Prices $3 Billion Notes at 4.25%-4.90% Across Four Maturities — May 15, 2026
Gilead Tops Q1 Estimates with 12% HIV, 28% Trodelvy Sales Growth — May 8, 2026
Gilead Cuts Full-Year Guidance, Expects Loss on Acquired R&D Charges — May 7, 2026
California High Court Weighs Gilead’s Liability to 24,000 HIV Patients Over TAF — May 6, 2026
Gilead to Expand ADC Pipeline with $5 Billion Tubulis Deal, Shares Up 1.97% — Apr 8, 2026

Recent GILD Insider Trades

Dickinson Andrew D sold 3.00K (~$396.81K) on May 15, 2026.
Mercier Johanna sold 7.75K (~$1.01M) on May 15, 2026.
Mercier Johanna sold 11.18K (~$1.47M) on May 15, 2026.

GILD Analyst Consensus

22 analysts cover GILD: 0 strong buy, 18 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $159.83.

Common questions about GILD

Which politicians traded GILD stock?: Recent politician trading activity in GILD includes disclosures from Josh Gottheimer, Val Hoyle, Marjorie Taylor Greene, Josh Gottheimer, and Marjorie Taylor Greene. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in GILD?: Yes. Rallies tracks politician and congressional stock disclosures for GILD, including reported purchases, sales, dates, owners, and trade amounts when available.
Is GILD research on Rallies investment advice?: No. Rallies provides research, data, and educational context for GILD. It does not provide personalized investment advice.